BRPI1011074A2 - composição estabilizada que compreende pelo menos um composto adrenérgico - Google Patents

composição estabilizada que compreende pelo menos um composto adrenérgico

Info

Publication number
BRPI1011074A2
BRPI1011074A2 BRPI1011074A BRPI1011074A BRPI1011074A2 BR PI1011074 A2 BRPI1011074 A2 BR PI1011074A2 BR PI1011074 A BRPI1011074 A BR PI1011074A BR PI1011074 A BRPI1011074 A BR PI1011074A BR PI1011074 A2 BRPI1011074 A2 BR PI1011074A2
Authority
BR
Brazil
Prior art keywords
stabilized composition
adrenergic compound
adrenergic
compound
stabilized
Prior art date
Application number
BRPI1011074A
Other languages
English (en)
Inventor
Alan J Baillie
Kenneth Macdonald
Pamela Porteous
Simon Hendry
Original Assignee
Alk Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alk Ag filed Critical Alk Ag
Publication of BRPI1011074A2 publication Critical patent/BRPI1011074A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI1011074A 2009-06-04 2010-06-03 composição estabilizada que compreende pelo menos um composto adrenérgico BRPI1011074A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18406609P 2009-06-04 2009-06-04
DKPA200900705 2009-06-04
PCT/EP2010/057771 WO2010139751A2 (en) 2009-06-04 2010-06-03 Stabilised composition comprising at least one adrenergic compound

Publications (1)

Publication Number Publication Date
BRPI1011074A2 true BRPI1011074A2 (pt) 2016-04-12

Family

ID=41364279

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI1013019A BRPI1013019A2 (pt) 2009-06-04 2010-06-03 composição estabilizada que compreende pelo menos um composto adrenérgico
BRPI1011074A BRPI1011074A2 (pt) 2009-06-04 2010-06-03 composição estabilizada que compreende pelo menos um composto adrenérgico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI1013019A BRPI1013019A2 (pt) 2009-06-04 2010-06-03 composição estabilizada que compreende pelo menos um composto adrenérgico

Country Status (15)

Country Link
US (1) US9155694B2 (pt)
EP (2) EP2437782B1 (pt)
JP (2) JP6087145B2 (pt)
KR (2) KR20120028344A (pt)
CN (3) CN106109397A (pt)
AU (2) AU2010255748B2 (pt)
BR (2) BRPI1013019A2 (pt)
CA (2) CA2764051A1 (pt)
DK (2) DK2437782T3 (pt)
ES (2) ES2432164T3 (pt)
MX (2) MX2011012732A (pt)
PT (2) PT2437781E (pt)
RU (2) RU2527337C9 (pt)
SI (2) SI2437782T1 (pt)
WO (2) WO2010139751A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8628805B2 (en) * 2009-06-04 2014-01-14 Alk Ag Stabilized composition comprising at least one adrenergic compound
CN102525893B (zh) * 2012-01-04 2013-11-20 上海禾丰制药有限公司 盐酸去氧肾上腺素注射液及其制剂工艺
CN102525894A (zh) * 2012-01-04 2012-07-04 上海禾丰制药有限公司 盐酸异丙肾上腺素注射液及其制剂工艺
US20150246009A1 (en) * 2012-10-08 2015-09-03 Wockhardt Limited Stable injectable pharmaceutical composition of epinephrine or salts thereof
TWI780236B (zh) * 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
MX2016004257A (es) * 2013-10-03 2016-08-17 Imprimis Pharmaceuticals Inc Composiciones oftalmicas basadas en epinefrina para la administracion intraocular y metodos para su frabricacion.
CN103520096B (zh) * 2013-10-25 2015-02-25 成都晶博生物科技有限责任公司 一种硫酸特布他林注射液的生产工艺
CN113230486A (zh) * 2013-12-18 2021-08-10 温德加普医疗股份有限公司 药物混合和递送系统及方法
US9839692B2 (en) 2014-01-09 2017-12-12 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
UY35988A (es) 2014-02-27 2015-09-30 Sint Sa Proceso para la producción de una solución inyectable de noradrenalina de baja concentración
PL2990031T3 (pl) 2014-08-28 2020-05-18 Sun Pharmaceutical Industries Ltd Pozajelitowa postać norepinefryny
JP2017538731A (ja) * 2014-12-18 2017-12-28 ウィンドギャップ メディカル， インコーポレイテッド 治療剤を溶解または可溶化するための方法および組成物。
US9119876B1 (en) * 2015-03-13 2015-09-01 Par Pharmaceutical, Inc. Epinephrine formulations
US20170189352A1 (en) 2015-03-13 2017-07-06 Par Pharmaceutical, Inc. Epinephrine formulations
US10039710B2 (en) * 2015-09-18 2018-08-07 Insys Development Company, Inc. Epinephrine spray formulations
US11517525B2 (en) * 2015-09-18 2022-12-06 Hikma Pharmaceuticals Usa Inc. Epinephrine spray formulations
JP2019524896A (ja) 2016-08-25 2019-09-05 ハーロウ・ヘルス・インコーポレイテッドＨａｒｒｏｗ Ｈｅａｌｔｈ， Ｉｎｃ． 眼内投与のためのエピネフリンベースの眼科組成物及びその製造方法
RU2635759C1 (ru) * 2016-09-13 2017-11-15 Интеллег Сосьете Анониме Фармацевтическая композиция для парентерального введения и способ ее получения
US10835503B2 (en) * 2017-01-13 2020-11-17 Teva Pharmaceuticals Usa, Inc. Pre-filled syringe
WO2018140894A1 (en) 2017-01-30 2018-08-02 Nevakar, Inc Norepinephrine compositions and methods therefor
ES2960528T3 (es) * 2017-04-17 2024-03-05 Hikma Pharmaceuticals Usa Inc Formulaciones de epinefrina en aerosol
WO2019067505A1 (en) * 2017-09-26 2019-04-04 Ys Pharmtech STABILIZATION OF EPINEPHRINE FORMULATIONS
CA3078266A1 (en) * 2017-10-10 2019-04-18 Merck Patent Gmbh Stabilized injectable pharmaceutical compositions of l-epinephrine
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CA3093725C (en) 2018-03-23 2021-08-24 Nevakar Inc. Epinephrine compositions and containers
AU2019252409B2 (en) 2018-04-11 2023-05-18 QuVa Pharma, Inc. Ready to use liquid RECK formulation
US10952962B1 (en) 2018-04-11 2021-03-23 QuVa Pharma, Inc. Ready to use liquid formulation
US10478406B2 (en) 2019-03-18 2019-11-19 HARC Therapeutics AG High-pH solid-state epinephrine formulation
CN116474219A (zh) * 2019-06-28 2023-07-25 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
WO2021024237A1 (en) 2019-08-08 2021-02-11 Sun Pharmaceutical Industries Limited Infusion dosage form of norepinephrine
USD1004518S1 (en) 2019-09-09 2023-11-14 Brunswick Corporation Railing for a marine vessel
USD984953S1 (en) 2021-05-03 2023-05-02 Brunswick Corporation Safely railing having buoy holder
AU2021203856B2 (en) * 2021-06-10 2023-03-09 Animal Ethics Pty Ltd Topical anaesthetic composition having improved vasoconstrictor stability
WO2024047474A1 (en) * 2022-08-27 2024-03-07 Biophore India Pharmaceuticals Pvt. Ltd Trientine liquid dosage forms

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB425678A (en) 1933-06-15 1935-03-15 Novocol Chemical Mfg Co Inc Improvements relating to anesthetics for hypodermic injection
US2047144A (en) * 1934-03-26 1936-07-07 Lilly Co Eli Stabilized epinephrine-type compound, and process of stabilizing it
US2382546A (en) * 1941-11-03 1945-08-14 Curtis David Anesthetic solutions
NL277824A (pt) 1961-04-28
US3419035A (en) * 1965-05-25 1968-12-31 Badger Meter Mfg Co Air elimination device for liquid transport system
CA981182A (en) 1972-01-07 1976-01-06 Walter A. Borisenok Stabilization of 1-epinephrine in local anesthetic solutions with a combination of three antioxidants
US3966905A (en) * 1973-05-29 1976-06-29 Barnes-Hind Pharmaceuticals, Inc. Stabilized catechol amine solutions
DD150694A1 (de) 1980-04-16 1981-09-16 Gisela Raether Verfahren zur stabilisierung von pharmazeutischen praeparaten mit oxidationsempfindlichen bestandteilen
US4734438A (en) 1983-04-26 1988-03-29 Macri Frank J Norepinephrine potentiated compositions and method of use
AU5680994A (en) 1992-12-10 1994-07-04 Abbott Laboratories Stabilized catecholamine solutions
JP3535537B2 (ja) * 1993-04-15 2004-06-07 日本製薬株式会社 静脈注射剤
US6077545A (en) 1995-10-30 2000-06-20 Matrix Pharmaceuticals, Inc. Process and composition for therapeutic cisplatin (CDDP)
WO1998020869A2 (en) 1996-11-14 1998-05-22 Alza Corporation Formulation for electrically assisted delivery of lidocaine and epinephrine
KR100514963B1 (ko) 1997-07-11 2005-09-15 도레이 가부시끼가이샤 4,5-에폭시모르피난 유도체를 함유하는 안정한 의약품 조성물
JP4393641B2 (ja) 1998-11-26 2010-01-06 久光製薬株式会社 イオントフォレーシス用粘着ゲル組成物及びその装置
EP1326642A2 (en) 2000-09-29 2003-07-16 Board of Trustees operating Michigan State University Catecholamine pharmaceutical compositions and methods
WO2005033143A1 (ja) 2003-10-01 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 抗体の安定化方法及び安定化された溶液状抗体製剤
UA71839C2 (uk) * 2003-12-30 2007-06-25 Товариство З Обмеженою Відповідальністю "Фарм-Стом" Фармацевтична композиція на основі артикаїну та епінефрину
US20050228336A1 (en) 2004-04-07 2005-10-13 Preston Keusch Electrically assisted lidocaine and epinephrine delivery device having extended shelf-stability
US20060129122A1 (en) 2004-12-06 2006-06-15 Wyrick Ronald E Method and apparatus for delivering epinephrine
CA2648578A1 (en) * 2006-04-03 2007-11-01 Nutramax Laboratories, Inc. Stabilized pentosan polysulfate (pps) formulations and methods of analyzing them
US20070249727A1 (en) * 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US20080269347A1 (en) * 2006-09-28 2008-10-30 Azopharma, Inc. Epinephrine formulations
US8628805B2 (en) 2009-06-04 2014-01-14 Alk Ag Stabilized composition comprising at least one adrenergic compound

Also Published As

Publication number Publication date
SI2437781T1 (sl) 2013-12-31
EP2437781A2 (en) 2012-04-11
SI2437782T1 (sl) 2013-12-31
RU2011153403A (ru) 2013-07-20
ES2432164T3 (es) 2013-12-02
AU2010255747A1 (en) 2012-02-02
PT2437782E (pt) 2013-10-30
CA2764050A1 (en) 2010-12-09
EP2437782B1 (en) 2013-07-24
JP6087145B2 (ja) 2017-03-01
KR20120028344A (ko) 2012-03-22
JP2012528830A (ja) 2012-11-15
EP2437782A2 (en) 2012-04-11
KR20120044309A (ko) 2012-05-07
RU2527337C2 (ru) 2014-08-27
RU2527680C2 (ru) 2014-09-10
WO2010139752A2 (en) 2010-12-09
JP2012528831A (ja) 2012-11-15
CA2764050C (en) 2017-02-28
ES2432241T3 (es) 2013-12-02
EP2437781B1 (en) 2013-07-24
CA2764051A1 (en) 2010-12-09
CN106109397A (zh) 2016-11-16
US20120129944A1 (en) 2012-05-24
MX2011012735A (es) 2012-02-28
WO2010139752A3 (en) 2011-04-07
AU2010255748B2 (en) 2014-03-13
CN102497882A (zh) 2012-06-13
WO2010139751A3 (en) 2011-04-07
AU2010255747B2 (en) 2014-03-13
AU2010255748A1 (en) 2011-12-08
MX2011012732A (es) 2012-02-28
RU2011153410A (ru) 2013-07-20
WO2010139751A2 (en) 2010-12-09
US9155694B2 (en) 2015-10-13
DK2437782T3 (da) 2013-10-28
PT2437781E (pt) 2013-10-30
BRPI1013019A2 (pt) 2016-03-29
CN102802668A (zh) 2012-11-28
RU2527337C9 (ru) 2014-12-27
DK2437781T3 (da) 2013-10-21

Similar Documents

Publication Publication Date Title
BRPI1013019A2 (pt) composição estabilizada que compreende pelo menos um composto adrenérgico
BRPI0914746A2 (pt) composições fungicidas
BRPI0921799A2 (pt) compostos que expandem células-tronco hematopoéticas
BRPI0918602A2 (pt) composto (i)
BRPI0906749A2 (pt) Composição
BRPI0913808A2 (pt) composição
DK2288375T3 (da) Pegylerede insulin-lispro-forbindelser
BRPI0920707A2 (pt) compostos
DK2242759T3 (da) Forbindelser
DK2634231T3 (da) Sammensætninger
BRPI0922959A8 (pt) composições herbicidas contendo compostos de benzoilpirazol
BRPI0919155A2 (pt) composição aquosa injetável
FR2944289B1 (fr) Composition huileuse volatile
DK2373293T3 (da) Sammensætninger med reduceret dimerdannelse
BRPI0917231A2 (pt) composição
DK2323972T3 (da) C7-fluor-substituerede tetracylinforbindelser
DK2297162T3 (da) Forbindelser
DK2308869T3 (da) Azolforbindelse
DE112009005504A5 (de) Schmiermittelzusammensetzung
BRPI0919037A2 (pt) composições lubrificantes
BRPI0908558A2 (pt) composição lubrificante
BRPI0916432A2 (pt) compostos
BRPI0912716A2 (pt) composto.
BRPI0923592A2 (pt) composto
BRPI0911393A2 (pt) composto de 5-hidroxipirimidina-4-carboxamida

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ALK-ABELLO A/S (DK)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2465 DE 03-04-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.